Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by general360on Mar 03, 2021 9:00am
193 Views
Post# 32703207

RE:New Published Evidence of Apabetalone’s Beneficial Effects o

RE:New Published Evidence of Apabetalone’s Beneficial Effects o
awesome, thanks for posting!  ABOUT TIME!!!

BUT.....sigh.....more questions remain, at least for me!  What journal is this published in?  I think it matters, it might not, guess we'll set at market open, bc:

Unfortunately, from this NR: "The article, titled: “Bromodomain and Extraterminal Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection (Pre-Clinical)”, was published on the pre-print server, bioRxiv, at the request of the reviewing scientific journal."

So, what journal?  Hopefully bioRxiv is not the extent of publishing cause...

from wikipedia: https://en.wikipedia.org/wiki/BioRxiv

"As preprints, papers hosted on bioRxiv are not peer-reviewed, but undergo basic screening and checked against plagiarism."

so, is our paper some fluff piece posted online, dressed up as something that hasn't been peer-reviewed and not published in a bone-fide respected journal?

And this:
https://www.biorxiv.org/about/FAQ
"bioRxiv is not a journal so it has no Impact Factor."

So we're not "published" yet?  This is going to a real journal?  or this is as good of a publication as we're gonna get"

if this is the only exposure, then my guess is this won't do much for us, sorry.....

why is nothing easy with this company?!?!?!?!?! anyways, i'll be hawking the opening bell as i'm sure we all will be....
<< Previous
Bullboard Posts
Next >>